SAB Biotherapeutics founds Clinical Advisory Board for SAB-142 development

SAB Biotherapeutics announced the founding of a clinical advisory board to provide expert insight and guidance to the Company in the clinical development of SAB-142, its leading therapeutic candidate. The newly formed board is comprised of world-leading experts with deep clinical expertise and strategic insight into the development of T1D therapies. As the Company works to advance the frontiers of clinical and medical research in disease-modifying therapies for T1D, the clinical advisory board is expected to play a critical role in providing strategic direction, insights on clinical protocols and strategies, and development of research initiatives. Founding Members of SAB BIO Clinical Advisory Board Colin Mark Dayan, MA, MBBS, FRCP, PhD, Professor of Clinical Diabetes and Metabolism at Cardiff University School of Medicine; Michael Haller, MD, Professor and Chief Silverstein Family Eminent Scholar at University of Florida; Stephen Gitelman, MD, Professor Pediatrics at University of California, San Francisco; Thomas Kay, MBBS, PhD, Professor of Medicine at University of Melbourne; Chantal Mathieu, MD, PhD, Professor of Medicine at Katholieke Universiteit Leuven; Jay S. Skyler, MD, MACP, FRCP Professor of Medicine, Pediatrics, & Psychology, in the Division of Endocrinology Diabetes & Metabolism, Department of Medicine, at University of Miami Leonard M. Miller School of Medicine, Miami, Florida; John Wentworth MBBS, FRACP, Professor of Medicine at Royal Melbourne Hospital.